Adlai Nortye (ANL) financial statements

Healthcare · Biotechnology · Market cap $975M

Net income was -$52M.

Free cash flow was -$52M.

The diluted share count rose 276% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions.

-0.1-0.100.12021202220232024RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, from Adlai Nortye's 10-K filings with the SEC.

Fiscal year2021202220232024
Revenue$46M—$5M—
Research and development$42M$54M$58M$45M
Selling, general and admin$12M$13M$15M$10M
Operating income-$9M-$67M-$73M-$53M
Interest expense$1M$433,000$791,000$2M
Pre-tax income-$57M-$59M-$109M-$52M
Income tax——$643,000—
Net income-$57M-$59M-$109M-$52M
EPS (diluted)-$2.23-$2.31-$2.52-$0.54
Diluted shares25M25M43M96M
Operating margin-18.9%—-1451.0%—
Net margin-124.0%—-2184.6%—

Balance sheet

Fiscal years, from Adlai Nortye's 10-K filings with the SEC.

Fiscal year2021202220232024
Cash and short-term investments$64M$43M$91M$61M
Total current assets—$66M$101M$64M
Property, plant and equipment$4M$4M$3M$2M
Total assets—$73M$130M$71M
Total current liabilities—$313M$50M$45M
Total liabilities—$314M$55M$46M
Shareholders' equity-$185M-$241M$75M$25M
Net debt-$64M-$38M-$61M-$35M

Cash flow

Fiscal years, from Adlai Nortye's 10-K filings with the SEC.

Fiscal year2021202220232024
Operating cash flow-$3M-$43M-$57M-$52M
Capital spending$1M$1M$200,000$170,000
Free cash flow-$4M-$44M-$57M-$52M
Stock-based compensation$3M$6M$4M$2M
Net borrowing$2M-$5M$26M-$4M
Free cash flow margin-9.1%—-1137.0%—
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ANL.
Open ANL in Investingly

Questions

How much free cash flow does Adlai Nortye generate?

-$52M in fiscal 2024 (operating cash flow minus capital spending).

From Adlai Nortye's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.